Back to Search
Start Over
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
- Source :
-
Haematologica [Haematologica] 2012 Feb; Vol. 97 (2), pp. 279-87. Date of Electronic Publication: 2011 Oct 11. - Publication Year :
- 2012
-
Abstract
- Background: CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lymphocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed.<br />Design and Methods: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lymphocytic leukemia and compared this to other biological and clinical prognosticators.<br />Results: CD69 was associated with Rai stages (P=0.00002), β(2)-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 and ZAP-70 (P=0.018) or CD38 (P=0.00015) or immunoglobulin variable heavy chain gene mutations (P=0.0005) were also significantly correlated. Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0.0001), and presented a shorter duration of response after fludarabine plus rituximab (P=0.010) as well as shorter progression free survival and overall survival (P<0.0001). CD69 demonstrated true additive prognostic properties, since the CD69(+) plus ZAP-70(+) or CD38(+) or immunoglobulin variable heavy chain gene unmutated patients had the worst progression free survival and overall survival (P<0.0001). Interestingly, low CD69 expression was necessary to correctly prognosticate the longer progression free survival of patients with a low tumor burden of β(2)-microglobulin (P=0.002), of soluble CD23 (P=0.020), or of Rai stages 0-I (P=0.005). CD69 was confirmed to be an independent prognostic factor in multivariate analysis of progression free survival (P=0.017) and overall survival (P=0.039).<br />Conclusions: Our data indicate that CD69 is significantly correlated with poor clinical and biological prognostic factors and is confirmed to be an independent disease prognosticator. This supports its introduction in a routine laboratory assessment and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia, after an adequate standardization process.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived administration & dosage
Antigens, CD genetics
Antigens, Differentiation, T-Lymphocyte genetics
Biomarkers, Tumor genetics
Cohort Studies
Female
Humans
Lectins, C-Type genetics
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Male
Middle Aged
Prognosis
Rituximab
Vidarabine administration & dosage
Vidarabine analogs & derivatives
Antigens, CD metabolism
Antigens, Differentiation, T-Lymphocyte metabolism
Biomarkers, Tumor metabolism
Lectins, C-Type metabolism
Leukemia, Lymphocytic, Chronic, B-Cell diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1592-8721
- Volume :
- 97
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 21993667
- Full Text :
- https://doi.org/10.3324/haematol.2011.052829